Gan & Lee Pharmaceuticals Co Ltd (603087.SS) stock: key figures, P/E, revenue and dividend

Health Care · Health Care Equipment · China · ISIN CNE100003ZH1

Price
69.45 CNY
Market cap
41.48 bn CNY
P/E (2025)
36.27
P/S (2025)
10.24
Dividend yield
1.44 %
Net margin
28.22 %
Return on equity (ROE)
9.83 %
Return on assets (ROA)
9.06 %

Gan & Lee Pharmaceuticals Co Ltd financials

Fiscal year20242025
Revenue3.05 bn CNY4.05 bn CNY
Gross profit2.27 bn CNY3.07 bn CNY
Operating income631.54 m CNY793.63 m CNY
EBIT294.58 m CNY1.23 bn CNY
Net income614.66 m CNY1.14 bn CNY
Diluted EPS – continuing operations1.04 CNY1.91 CNY

Full history since 2013, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Gan & Lee Pharmaceuticals Co Ltd

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the development, production, and commercialization of insulin analogs and medical devices in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection device; and GanleeFine, an insulin pen needle. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 20.10.2026. Details in the risk notice.

Gan & Lee Pharmaceuticals Co Ltd stock (603087.SS): P/E, revenue, dividend | finmetric